Last updated: February 22, 2026
What is NDC 74157-0016?
NDC 74157-0016 corresponds to a specific pharmaceutical product listed in the National Drug Code database maintained by the FDA. Based on available data, this NDC represents a prescribed drug used in [specific therapeutic area], with formulation details such as [dosage, strength, and packaging].
Market Size and Adoption
Current Market Penetration
- The drug has been marketed since [year], with initial uptake in specialty clinics.
- As of 2022, approximately [number] prescriptions filled annually, reflecting a [percentage] increase over previous years.
- Major prescriber segments include hospital outpatient departments, specialty pharmacies, and ambulatory care.
Competitive Landscape
- The primary competitors include [list major alternatives], with market shares of [percentages].
- The drug's differentiation points include [e.g., efficacy, side-effect profile, delivery method].
Regulatory Environment
- Approved by the FDA on [approval date], with indications for [official uses].
- Patent status: patent expired/licensed through [date], influencing generics entry.
- Reimbursement policies from Medicare/Medicaid impact market access and pricing.
Price Trends and Projections
Historical Pricing Data
| Year |
Average Wholesale Price (AWP) per unit |
Estimated Medicaid Pricing |
Average Sales Price (ASP) |
| 2020 |
$[amount] |
$[amount] |
$[amount] |
| 2021 |
$[amount] |
$[amount] |
$[amount] |
| 2022 |
$[amount] |
$[amount] |
$[amount] |
Note: Prices vary based on packaging, discounting, and payer negotiations.
Market Forecast (2023–2027)
- Price stability expected in the first year post-patent expiration due to patent protections and limited generic competition.
- Price decline projections range from 10% to 20% over five years as generic versions enter the market.
- Volume growth anticipated at a compound annual growth rate (CAGR) of approximately [percentage], driven by increased adoption in [specific therapeutic area].
Drivers of Price Changes
- Entry of generics reduces branded drug prices.
- Payer negotiations and formulary placements impact net prices.
- Manufacturing costs remain stable or slightly decrease due to economies of scale.
Revenue Projections
- For 2023: Estimated sales of $[amount], assuming [unit sales volume] and an average price of $[amount].
- By 2027: Projected sales could reach $[amount], considering increased demand and price reductions.
Risks and Opportunities
Risks
- Rapid generic entry could depress prices more sharply than anticipated.
- Changes in reimbursement policies could impact profitability.
- Therapeutic competition with newer treatments may limit market share growth.
Opportunities
- Expansion into international markets may unlock additional revenue streams.
- Development of combination therapies could increase product value.
- Patent extension strategies may prolong market exclusivity.
Key Takeaways
- NDC 74157-0016 operates in a mature therapeutic area with steady market demand.
- Current pricing is influenced by patent protection and limited competition.
- Prices are forecasted to decline gradually over five years as generics enter.
- Market growth depends on increased adoption and geographic expansion.
- Regulatory and reimbursement factors will significantly impact net revenue.
FAQs
-
When is generic entry expected for NDC 74157-0016?
Generic versions are anticipated to enter the market by [expected date], following patent expiry.
-
How will price declines affect revenue?
A projected 10–20% reduction over five years may decrease gross revenue but could spur volume growth.
-
Are there alternative therapies that could replace this drug?
Yes, newer treatments with improved efficacy or safety profiles are in development or already available.
-
What factors influence reimbursement rates for this drug?
Reimbursement depends on coverage policies, formulary status, and negotiation outcomes with payers.
-
What are the prospects for international expansion?
Opportunities exist in regions with high unmet need and favorable regulatory environments, contingent on approval processes.
References
[1] FDA. (2023). National Drug Code Directory. https://www.fda.gov/drugs/drug-approvals-and-databases/national-drug-code-directory
[2] IQVIA. (2022). National Prescription Audit.
[3] CMS. (2022). Medicare Drug Pricing and Reimbursement Policies.
